From: Genetically modified mesenchymal stem cell therapy for acute respiratory distress syndrome
ClinicalTrials.gov identifier | Study title | Study phase | Actual/estimated enrollment | Cell source | Cell does | Primary outcome | Location | Status |
---|---|---|---|---|---|---|---|---|
NCT01775774 | Human mesenchymal stem cells for acute respiratory distress syndrome (START) | Phase 1 | 9 participants | Bone marrow MSCs | 1 × 106,5 × 106, and 10 × 106 cells/kg | Infusion associated adverse events | USA | Completed |
NCT03608592 | Human umbilical cord-derived mesenchymal stem cells therapy in acute respiratory distress syndrome | Phase 1 | 12 participants | Umbilical cord-derived MSCs | 1 × 106 cells | Infusion associated events | China | Not yet recruiting |
NCT02804945 | Mesenchymal stem cells (MSCs) for treatment of acute respiratory distress syndrome (ARDS) in patients with malignancies | Phase 1 | 20 participants | Bone marrow MSCs | 3 × 106/cells/kg | Adverse events | USA | Active, not recruiting |
NCT01902082 | Adipose-derived mesenchymal stem cells in acute respiratory distress syndrome | Phase 1 | 20 participants | Adipose-derived MSCs | 1 × 106/cells/kg | Adverse events | China | Completed |
NCT02444455 | Human umbilical-cord-derived mesenchymal stem cell therapy in acute lung injury (UCMSC-ALI) | Phase 1/2 | 20 participants | Human umbilical cord MSCs | 5 × 105/cells/kg | Major adverse events | China | Recruiting |
NCT02112500 | Mesenchymal stem cell in patients with acute severe respiratory failure (STELLAR) | Phase 2 | 10 participants | Bone marrow MSCs | Unclear | Oxygen index at 3 days after MSCs infusion | Korea | Unknown |
NCT03042143 | Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) | Phase 1/2 | 75 participants | Umbilical cord-derived MSCs | Unclear | Oxygenation index, serious adverse events | UK | Recruiting |